Search Results - "SLATER, Shannon"

Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study by Connolly, Roisin M, Li, Huili, Jankowitz, Rachel C, Zhang, Zhe, Rudek, Michelle A, Jeter, Stacie C, Slater, Shannon A, Powers, Penny, Wolff, Antonio C, Fetting, John H, Brufsky, Adam, Piekarz, Richard, Ahuja, Nita, Laird, Peter W, Shen, Hui, Weisenberger, Daniel J, Cope, Leslie, Herman, James G, Somlo, George, Garcia, Agustin A, Jones, Peter A, Baylin, Stephen B, Davidson, Nancy E, Zahnow, Cynthia A, Stearns, Vered

“…In breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor led to reexpression of genes…”
Get full text

Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood by HIGGINS, Michaela J, JELOVAC, Danijela, EMENS, Leisha, RILEY, Carol, STEARNS, Vered, DIEHL, Frank, ANGENENDT, Philipp, PENG HUANG, COPE, Leslie, ARGANI, Pedram, MURPHY, Kathleen M, BACHMAN, Kurtis E, BARNATHAN, Evan, GRESHOCK, Joel, WOLFF, Antonio C, PARK, Ben H, BLAIR, Brian, SLATER, Shannon, POWERS, Penny, ZORZI, Jane, JETER, Stacie C, OLIVER, George R, FETTING, John

“…We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating tumor DNA (ctDNA) from plasma of patients with metastatic breast cancer…”
Get full text

Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer by STEARNS, Vered, JACOBS, Lisa K, POWERS, Penny, BRIEST, Susanne, CHAO, Calvin, YOSHIZAWA, Carl, SUGAR, Elizabeth, ESPINOZA-DELGADO, Igor, SUKUMAR, Saraswati, GABRIELSON, Edward, DAVIDSON, Nancy E, FACKLER, MaryJo, TSANGARIS, Theodore N, RUDEK, Michelle A, HIGGINS, Michaela, LANGE, Julie, CHENG, Zandra, SLATER, Shannon A, JETER, Stacie C

“…Agents that target the epigenome show activity in breast cancer models. In preclinical studies, the histone deacetylase inhibitor vorinostat induces cell-cycle…”
Get full text

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer by Higgins, Michaela J., Prowell, Tatiana M., Blackford, Amanda L., Byrne, Celia, Khouri, Nagi F., Slater, Shannon A., Jeter, Stacie C., Armstrong, Deborah K., Davidson, Nancy E., Emens, Leisha A., Fetting, John H., Powers, Pendleton P., Wolff, Antonio C., Green, Hannah, Thibert, Jacklyn N., Rae, James M., Folkerd, Elizabeth, Dowsett, Mitchell, Blumenthal, Roger S., Garber, Judy E., Stearns, Vered

“…Observational studies have demonstrated a decreased incidence of cancers among users of HMG CoA reductase inhibitors (statins) and a reduced risk of recurrence…”
Get full text

Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer by Parsons, Heather A, Beaver, Julia A, Cimino-Mathews, Ashley, Ali, Siraj M, Axilbund, Jennifer, Chu, David, Connolly, Roisin M, Cochran, Rory L, Croessmann, Sarah, Clark, Travis A, Gocke, Christopher D, Jeter, Stacie C, Kennedy, Mark R, Lauring, Josh, Lee, Justin, Lipson, Doron, Miller, Vincent A, Otto, Geoff A, Rosner, Gary L, Ross, Jeffrey S, Slater, Shannon, Stephens, Philip J, VanDenBerg, Dustin A, Wolff, Antonio C, Young, Lauren E, Zabransky, Daniel J, Zhang, Zhe, Zorzi, Jane, Stearns, Vered, Park, Ben H

“…The clinical utility of next-generation sequencing (NGS) in breast cancer has not been demonstrated. We hypothesized that we could perform NGS of a new biopsy…”
Get full text

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial by Santa-Maria, Cesar A., Bardia, Aditya, Blackford, Amanda L., Snyder, Claire, Connolly, Roisin M., Fetting, John H., Hayes, Daniel F., Jeter, Stacie C., Miller, Robert S., Nguyen, Anne, Quinlan, Katie, Rosner, Gary L., Slater, Shannon, Storniolo, Anna Maria, Wolff, Antonio C., Zorzi, Jane, Henry, Nora Lynn, Stearns, Vered

“…Purpose Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a…”
Get full text

A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial by Santa-Maria, Cesar Augusto, Bardia, Aditya, Blackford, Amanda, Connolly, Roisin M., Fetting, John H., Jeter, Stacie, Miller, Robert Stephen, Nguyen, Anne T, Quinlan, Katie, Slater, Shannon, Snyder, Claire Frances, Wolff, Antonio C., Zorzi, Jane, Henry, N. Lynn, Stearns, Vered

“…Abstract only…”
Get full text

Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer by Connolly, Roisin M., Jankowitz, Rachel Catherine, Zahnow, Cynthia A., Zhang, Zhe, Rudek, Michelle A., Slater, Shannon, Powers, Penny, Jeter, Stacie, Brufsky, Adam, Piekarz, Richard, Herman, James Gordon, Ahuja, Nita, Somlo, George, Garcia, Agustin A., Baylin, Stephen, Davidson, Nancy E., Stearns, Vered

“…Abstract only…”
Get full text

Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial by Bardia, Aditya, Santa-Maria, Cesar Augusto, Jacobs, Lisa K., Cimino-Mathews, Ashley, Huang, Peng, Russell, Stuart, Camp, Melissa, Habibi, Mehran, Lange, Julie R., Jeter, Stacie, Powers, Penny, Slater, Shannon, Gabrielson, Edward, Carducci, Michael Anthony, Semenza, Gregg, Stearns, Vered

“…Abstract only TPS1144 Background: Unlike normal cells, tumor cells thrive in a hypoxic microenvironment, and intratumoral hypoxia correlates with increased…”
Get full text

Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer by Connolly, Roisin M., Jankowitz, Rachel C., Zahnow, Cynthia A., Zhang, Zhe, Rudek, Michelle A., Jeter, Stacie C., Slater, Shannon, Powers, Penny, Wolff, Antonio C., Fetting, John, Brufsky, Adam M., Piekarz, Richard, Ahuja, Nita, Somlo, George, Garcia, Augustin, Baylin, Steven, Davidson, Nancy E., Stearns, Vered

“…Abstract Background: In preclinical breast cancer models, combination epigenetic therapy with a DNA methyltransferase inhibitor (DNMTI) and a histone…”
Get full text

African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women by Balmanoukian, Ani, Zhang, Zhe, Jeter, Stacie, Slater, Shannon, Armstrong, Deborah K, Emens, Leisha A, Fetting, John H, Wolff, Antonio C, Davidson, Nancy E, Jacobs, Lisa, Lange, Julie, Tsangaris, Theodore N, Zellars, Richard, Gabrielson, Edward, Stearns, Vered

Get full text